NCT03562806 is a NA clinical trial of PET/MR image acquisition in Lung Diseases, sponsored by University of Zurich.

Who is sponsoring NCT03562806?

NCT03562806 is sponsored by University of Zurich.

What drugs are being tested in NCT03562806?

Interventions in NCT03562806: PET/MR image acquisition.

What condition does NCT03562806 study?

NCT03562806 studies Lung Diseases.

Is NCT03562806 still recruiting?

NCT03562806 is currently terminated. Last updated 23 May 2022.

Last reviewed 2022-05-23 · How we verify

NCT03562806

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MRI 3D UTE Hyper-Cones & ZTE for PET/MR Lung Attenuation Correction & for Lung Diagnostic Imaging

Terminated NA Last updated 23 May 2022

What this trial tests

NA trial testing PET/MR image acquisition in Lung Diseases in 9 participants. Terminated before completion.

Timeline

23 May 2018

Primary endpoint
9 March 2021

9 March 2021

Quick facts

Lead sponsor	University of Zurich
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	9
Start date	23 May 2018
Primary completion	9 March 2021
Estimated completion	9 March 2021
Sites	1 location across Switzerland

Drugs / interventions tested

PET/MR image acquisition

Conditions studied

Lung Diseases — all drugs for Lung Diseases →

Sponsor

University of Zurich

Who can join

Adults 18 to 80, any sex, with Lung Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

MRI 3D UTE Hyper-Cones \& ZTE for PET/MR lung attenuation correction \& for lung diagnostic imaging

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Lung Diseases

Currently open trials in the same condition.

NCT07356076 — The Use of Electrical Impedance Tomography (EIT) in Pulmonary Diseases · recruiting
NCT07243964 — Multi-Omics-Based Prediction of Allograft Dysfunction After Lung Transplantation · recruiting
NCT07270744 — Data Collection Using Eko Devices in a Clinical Setting · recruiting
NCT07227376 — Data Collection Using Eko Digital Devices in a Clinical Setting · recruiting
NCT06917573 — PALACE: Cemiplimab Trial According to ctDNA Levels · Phase 2 · recruiting

Other University of Zurich trials

Trials by the same sponsor.

NCT07485699 — Soy Processing and Food Allergy · NA · not yet recruiting
NCT07516912 — Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland · not yet recruiting
NCT07473115 — Individualized Analgesia in the Intensive Care Unit With a New Pain Assessment Bundle and Protocolized Analgesia Adjustm · not yet recruiting
NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
NCT06481982 — Value of Advanced MRI Techniques in the Assessment of Endometriosis · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03562806 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Zurich
Last refreshed: 23 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03562806.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing